Experts has a new look! Let us know what you think of the updates.

Provide feedback
Home
Scholarly Works
Development of an inhaled anti-TSLP therapy for...
Journal article

Development of an inhaled anti-TSLP therapy for asthma

Abstract

Thymic stromal lymphopoietin (TSLP), an epithelial cell-derived cytokine, acts as a key mediator in airway inflammation and modulates the function of multiple cell types, including dendritic cells and group 2 innate lymphoid cells. TSLP plays a role in asthma pathogenesis as an upstream cytokine, and data suggest that TSLP blockade with the anti-TSLP monoclonal antibody, tezepelumab, could be efficacious in a broad asthma population. Currently …

Authors

O'Byrne PM; Panettieri RA; Taube C; Brindicci C; Fleming M; Altman P

Journal

Pulmonary Pharmacology & Therapeutics, Vol. 78, ,

Publisher

Elsevier

Publication Date

February 2023

DOI

10.1016/j.pupt.2022.102184

ISSN

1094-5539